High low-density lipoprotein cholesterol (LDL-C) levels have been established as a risk factor for fatal cardiovascular (CV) events, including acute coronary syndrome (ACS), whose principal pathogenesis is the disruption of culprit plaques composed of a large lipid core under a thin fibrous cap. This structure, termed thin-cap fibroatheroma (TCFA), is considered vulnerable. Statins or 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors can stabilize vulnerable coronary plaques by lowering LDL-C levels, and this stabilization prevents the occurrence of ACS. Clinical trials involving more than 170,000 participants conducted over two decades have demonstrated the beneficial effects of statins in reducing the risk of CV events by 25%; however, 75% of coronary events manifest despite treatment, possibly because of underlying residual risk [1] . The elevation of nonfasting serum triglyceride (TG) levels has been considered a residual risk factor for coronary artery disease (CAD) [2] . After food consumption, chylomicron (CM) and very-low-density lipoprotein (VLDL) are produced by the intestine and liver, respectively. After secretion, TGs contained in CM and VLDL particles are immediately hydrolyzed by lipoprotein lipase (LPL), and the resulting smaller CM and VLDL particles are termed remnants. CM remnants Editorial (CM-Rs) and a portion of VLDL remnants (VLDL-Rs) are removed from the circulation by the liver, and the remaining VLDL-Rs are transformed into LDL via hepatic TG lipase-induced hydrolyzation. CM, VLDL, CM-Rs, and VLDL-Rs are collectively termed triglyceride-rich lipoproteins (TGRLs). Postprandial hypertriglyceridemia is characterized by the accumulation of TGRL particles. Apolipoprotein B-100 (ApoB-100) exists on the surface of VLDL, VLDL-R, and LDL, and apolipoprotein B-48 (ApoB-48) exists on the surface of CM and CM-R. ApoB-100 and ApoB-48 are the primary structural component of lipoproteins. Serum ApoB-100 levels mainly reflect the number of LDL particles opposed to VLDL or VLDL-R particles because the number of LDL particle is greater than that of VLDL or VLDL-R particles in serum. The serum levels of ApoB-48 reflect the number of CM and CM-R particles. Our recent study identified an independent association between the presence of TCFA detected via a multivessel examination using optical coherence tomography and the increment of serum ApoB-48 levels compared with the fasting to peak values (ApoB-48) estimated using the meal tolerance test (MTT) in patients with stable CAD who underwent percutaneous coronary intervention (Figure 1) 
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